vs

Side-by-side financial comparison of EVERSPIN TECHNOLOGIES INC. (MRAM) and Verastem, Inc. (VSTM). Click either name above to swap in a different company.

EVERSPIN TECHNOLOGIES INC. is the larger business by last-quarter revenue ($14.9M vs $11.2M, roughly 1.3× Verastem, Inc.). EVERSPIN TECHNOLOGIES INC. runs the higher net margin — -2.0% vs -876.3%, a 874.3% gap on every dollar of revenue.

Everspin Technologies, Inc. is a publicly traded semiconductor company headquartered in Chandler, Arizona, United States. It develops and manufactures discrete magnetoresistive RAM or magnetoresistive random-access memory (MRAM) products, including Toggle MRAM and Spin-Transfer Torque MRAM (STT-MRAM) product families. It also licenses its technology for use in embedded MRAM (eMRAM) applications, magnetic sensor applications as well as performs backend foundry services for eMRAM.

Verastem, Inc., doing business as Verastem Oncology, is an American pharmaceutical company that develops medicines to treat certain cancers. Headquartered and founded in Boston, Massachusetts, the firm is a member of NASDAQ Biotechnology Index.

MRAM vs VSTM — Head-to-Head

Bigger by revenue
MRAM
MRAM
1.3× larger
MRAM
$14.9M
$11.2M
VSTM
Higher net margin
MRAM
MRAM
874.3% more per $
MRAM
-2.0%
-876.3%
VSTM

Income Statement — Q1 FY2026 vs Q3 FY2025

Metric
MRAM
MRAM
VSTM
VSTM
Revenue
$14.9M
$11.2M
Net Profit
$-296.0K
$-98.5M
Gross Margin
52.7%
Operating Margin
29.0%
-362.2%
Net Margin
-2.0%
-876.3%
Revenue YoY
13.2%
Net Profit YoY
-311.1%
EPS (diluted)
$-0.01
$-1.35

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
MRAM
MRAM
VSTM
VSTM
Q1 26
$14.9M
Q4 25
$14.8M
Q3 25
$14.1M
$11.2M
Q2 25
$13.2M
$2.1M
Q1 25
$13.1M
Q4 24
$13.2M
Q3 24
$12.1M
$0
Q2 24
$10.6M
$10.0M
Net Profit
MRAM
MRAM
VSTM
VSTM
Q1 26
$-296.0K
Q4 25
$1.2M
Q3 25
$54.0K
$-98.5M
Q2 25
$-670.0K
$-25.9M
Q1 25
$-1.2M
Q4 24
$1.2M
Q3 24
$2.3M
$-24.0M
Q2 24
$-2.5M
$-8.3M
Gross Margin
MRAM
MRAM
VSTM
VSTM
Q1 26
52.7%
Q4 25
50.8%
Q3 25
51.3%
Q2 25
51.3%
Q1 25
51.4%
Q4 24
51.3%
Q3 24
49.2%
Q2 24
49.0%
Operating Margin
MRAM
MRAM
VSTM
VSTM
Q1 26
29.0%
Q4 25
-7.2%
Q3 25
-11.0%
-362.2%
Q2 25
-14.9%
-2047.9%
Q1 25
-14.7%
Q4 24
-11.8%
Q3 24
-17.5%
Q2 24
-26.5%
-182.8%
Net Margin
MRAM
MRAM
VSTM
VSTM
Q1 26
-2.0%
Q4 25
8.1%
Q3 25
0.4%
-876.3%
Q2 25
-5.1%
-1213.6%
Q1 25
-8.9%
Q4 24
9.2%
Q3 24
18.8%
Q2 24
-23.5%
-82.6%
EPS (diluted)
MRAM
MRAM
VSTM
VSTM
Q1 26
$-0.01
Q4 25
$0.05
Q3 25
$0.00
$-1.35
Q2 25
$-0.03
$-0.62
Q1 25
$-0.05
Q4 24
$0.07
Q3 24
$0.10
$-0.60
Q2 24
$-0.12
$-0.31

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
MRAM
MRAM
VSTM
VSTM
Cash + ST InvestmentsLiquidity on hand
$40.5M
$137.7M
Total DebtLower is stronger
Stockholders' EquityBook value
$70.2M
$-15.5M
Total Assets
$83.2M
$176.9M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
MRAM
MRAM
VSTM
VSTM
Q1 26
$40.5M
Q4 25
$44.5M
Q3 25
$45.3M
$137.7M
Q2 25
$45.0M
$164.3M
Q1 25
$42.2M
Q4 24
$42.1M
Q3 24
$39.6M
$113.2M
Q2 24
$36.8M
$83.4M
Total Debt
MRAM
MRAM
VSTM
VSTM
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
$40.5M
Q2 24
$40.3M
Stockholders' Equity
MRAM
MRAM
VSTM
VSTM
Q1 26
$70.2M
Q4 25
$68.9M
Q3 25
$65.8M
$-15.5M
Q2 25
$64.1M
$36.1M
Q1 25
$63.0M
Q4 24
$62.6M
Q3 24
$59.3M
$11.1M
Q2 24
$55.4M
$18.9M
Total Assets
MRAM
MRAM
VSTM
VSTM
Q1 26
$83.2M
Q4 25
$84.6M
Q3 25
$80.3M
$176.9M
Q2 25
$78.9M
$196.3M
Q1 25
$80.2M
Q4 24
$77.8M
Q3 24
$72.6M
$126.4M
Q2 24
$64.6M
$105.7M
Debt / Equity
MRAM
MRAM
VSTM
VSTM
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
3.66×
Q2 24
2.14×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
MRAM
MRAM
VSTM
VSTM
Operating Cash FlowLast quarter
$570.0K
$-36.2M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
MRAM
MRAM
VSTM
VSTM
Q1 26
$570.0K
Q4 25
$2.6M
Q3 25
$881.0K
$-36.2M
Q2 25
$5.0M
$-32.7M
Q1 25
$1.4M
Q4 24
$3.8M
Q3 24
$2.8M
$-23.8M
Q2 24
$1.7M
$-27.6M
Free Cash Flow
MRAM
MRAM
VSTM
VSTM
Q1 26
Q4 25
$-975.0K
Q3 25
$543.0K
Q2 25
$3.0M
Q1 25
$527.0K
Q4 24
$2.1M
Q3 24
$2.8M
Q2 24
$1.7M
$-27.6M
FCF Margin
MRAM
MRAM
VSTM
VSTM
Q1 26
Q4 25
-6.6%
Q3 25
3.9%
Q2 25
22.9%
Q1 25
4.0%
Q4 24
15.8%
Q3 24
22.9%
Q2 24
15.9%
-275.8%
Capex Intensity
MRAM
MRAM
VSTM
VSTM
Q1 26
Q4 25
24.3%
Q3 25
2.4%
Q2 25
15.1%
Q1 25
6.9%
Q4 24
13.2%
Q3 24
0.5%
Q2 24
0.3%
0.1%
Cash Conversion
MRAM
MRAM
VSTM
VSTM
Q1 26
Q4 25
2.19×
Q3 25
16.31×
Q2 25
Q1 25
Q4 24
3.16×
Q3 24
1.25×
Q2 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

MRAM
MRAM

Product sales$14.1M95%
Licensing, royalty, patent, engineering services and other revenue$772.0K5%

VSTM
VSTM

Segment breakdown not available.

Related Comparisons